Hot flashes in peri and postmenopausal women. Menopausal and female climacteric states
Conditions
Interventions
Intervention 1: placebo: 20 drops,three times daily for 2 months. Intervention 2: Hypiran: 20 drops, three times daily for 2 months.
Placebo
Treatment - Drugs
Hypiran: 20 drops, three times daily for 2 months
placebo: 20 drops,three times daily for 2 months
Sponsors
Deputy of Research of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (1) natural perimenopuse (3-11 months of amenorrhea or increased menstrual irregularity if still cycling) or postmenopause (12 or more months of amenorrhea) (2) untreated complaints for at least 2 months, (3) no history of cancer, (4) moderate to severe hot flashes happening at least once a day, (5) lack of illnesses creating hot flash-like symptoms, (6) presenting the serum level of FSH more than 40 mlu/ml. Exclusion criteria: (1) treatment with sexual hormones, nonhormonal climacteric drugs, or any treatment to alleviate climacteric symptoms in the last 12 weeks before study entry, (2) treatment with chemical or plant-derived medicines in the last 12 weeks before study entry, (3) bilateral oophorectomy, and (4) severe diseases (e.g., of the heart, liver, kidney, alimentary system, or metabolic diseases) or abnormal thyroid-stimulating hormone value that could mimic climacteric complaints or the actual or expected treatment or that could interfere with the study objectives.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease of the severity, frequency and duration of hot flashes. Timepoint: one month. Method of measurement: Kupperman Index. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed